Latest From BeiGene Ltd.
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
Drug Discovery Tools
- Drug Discovery Tools
- In Vitro Diagnostics
- Therapeutic Areas
- BeiGene (Beijing) Co. Ltd.
- Parent & Subsidiaries
- BeiGene Ltd.
- Senior Management
John V Oyler, CEO
Howard Liang, PhD, CFO & Chief Strategy Officer
Guillaume Vignon, PhD, SVP, Bus. Dev.
- Contact Info
Phone: 10 851 48500
No. 30 Science Park Rd. Zhong-Guan-Cun
Life Science Pk
Changping District, 102206
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.